Low-grade risk of hypercoagulable state in patients suffering from diabetes mellitus type 2

Journal of Zhejiang University: Science B

Volumn 16, Issue 9, 2015, Pages 788-795

  Ruszkowska Ciastek, Barbara ^a,b   Sokup, Alina ^a,b   Wernik, Tomasz ^a,b   Rhone, Piotr ^a,b   Góralczyk, Krzysztof ^a,b   Bielawski, Kornel ^a,b   Fijałkowska, Agata ^a,b   Nowakowska, Aleksandra ^a,b   Rhone, Elżbieta ^a,b   Rość, Danuta ^a,b  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Angiogenesis; Diabetes; Extrinsic coagulation pathway; Glomerular filtration rate

Indexed keywords

ANTIPLASMIN; BLOOD CLOTTING FACTOR 7A; CALCIUM ION; CHOLESTEROL; CITRIC ACID; CREATININE; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EDETATE DISODIUM; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; METFORMIN; SULFONYLUREA DERIVATIVE; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; VASCULOTROPIN A; ANGIOGENIC PROTEIN; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES CONTROL; DIABETIC PATIENT; DIAGNOSTIC TEST ACCURACY STUDY; DIET RESTRICTION; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; INSULIN TREATMENT; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; RISK FACTOR; SERUM; BLOOD; COMORBIDITY; COMPLICATION; DIABETES MELLITUS, TYPE 2; PROCEDURES; REPRODUCIBILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THROMBOPHILIA;

AGED; ANGIOGENIC PROTEINS; BIOMARKERS; BLOOD COAGULATION FACTORS; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THROMBOPHILIA;

EID: 84941916598     PISSN: 16731581     EISSN: 18621783     Source Type: Journal    
DOI: 10.1631/jzus.B1500066     Document Type: Article

References (27)

1. Adams, M.J., Irish, A.B., Watts, G.F., et al., 2008. Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function. Thromb. Res., 123(2):374–380. [doi:10.1016/j.thromres.2008.03.024]
2. Alzahrani, S.H., Ajjan, R.A., 2010. Coagulation and fibrinolysis in diabetes. Diabetes Vasc. Dis. Res., 7(4):260–273. [doi:10.1177/1479164110383723]
3. Boden, G., Vaidyula, V.R., Homko, C., et al., 2007. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J. Clin. Endocrinol. Metab., 92(11):4352–4358. [doi:10.1210/jc.2007-0933]
4. Breitenstein, A., Tanner, F.C., Luscher, T.F., 2010. Tissue factor and cardiovascular disease: quo vadis? Circ. J., 74(1):3–12.
5. Chu, A.J., 2011. Tissue factor, blood coagulation, and beyond: an overview. Int. J. Inflam., 2011:367284. [doi:10.4061/ 2011/367284]
6. DelGiudice, L.A., White, G.A., 2009. The role of tissue factor and tissue factor pathway inhibitor in health and disease states. J. Vet. Emerg. Crit. Care (San Antonio), 19(1): 23–29. [doi:10.1111/j.1476-4431.2008.00380.x]
7. El-Hagracy, R.S., Kamal, G.M., Sabry, I.M., et al., 2010. Tissue factor, tissue factor pathway inhibitor and factor VII activity in cardiovascular complicated type 2 diabetes mellitus. Oman Med. J., 25(3):173–178. [doi:10.5001/omj.2010.52]
8. Ghafoor, F., Bano, K.A., Malik, T., et al., 2004. Microalbuminuria as an indicator of kidney function among diabetics. J. Coll. Phys. Surg. Pak., 14(11):670–672.
9. Hess, K., Grant, P.J., 2011. Inflammation and thrombosis in diabetes. Thromb. Haemost., 105(Suppl. 1):S43–S54. [doi:10.1160/THS10-11-0739]
10. Kacso, I.M., Bondor, C.I., Kacso, G., 2012. Soluble serum Klotho in diabetic nephropathy: relationship to VEGF-A. Clin. Biochem., 45(16-17):1415–1420. [doi:10.1016/j.clinbiochem.2012.07.098]
11. Kanesaki, Y., Suzuki, D., Uehara, G., et al., 2005. Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am. J. Kidney Dis., 45(2):288–294. [doi:10. 1053/j.ajkd.2004.09.020]
12. Kota, S.K., Meher, L.K., Jammula, S., et al., 2012. Aberrant angiogenesis: the gateway to diabetic complications. Indian J. Endocrinol. Metab., 16(6):918–930. [doi:10. 4103/2230-8210.102992]
13. Kowalski, J., Sliwczynska-Rodziewicz, D., Kowalczyk, E., et al., 2011. Plasma nitric oxide and vascular endothelial growth factor levels in patients with metabolic syndrome and co-existing vascular complications. Pol. Med. J., 30(178):249–252 (in Polish).
14. Kubisz, P., Chudy, P., Stasko, J., et al., 2010. Circulating vascular endothelial growth factor in the normo- and/or microalbuminuric patients with type 2 diabetes mellitus. Acta Diabetol., 47(2):119–124. [doi:10.1007/s00592-009-0127-2]
15. Lizakowski, S., Zdrojewski, Z., Jagodzinski, P., et al., 2007. Plasma tissue factor and tissue factor pathway inhibitor in patients with primary glomerulonephritis. Scand. J. Urol. Nephrol., 41(3):237–242. [doi:10.1080/00365590601016 511]
16. Mahdy, R.A., Nada, W.M., Hadhoud, K.M., et al., 2010. The role of vascular endothelial growth factor in the progression of diabetic vascular complications. Eye (Lond.), 24(10):1576–1584. [doi:10.1038/eye.2010.86]
17. Malyszko, J., Malyszko, J.S., Mysliwiec, M., 2004. Endothelial cell injury markers in chronic renal failure on conservative treatment and continuous ambulatory peritoneal dialysis. Kidney Blood Press. Res., 27(2):71–77. [doi:10.1159/000075810]
18. Olokoba, A.B., Obateru, O.A., Olokoba, L.B., 2012. Type 2 diabetes mellitus: a review of current trends. Oman Med. J., 27(4):269–273. [doi:10.5001/omj.2012.68]
19. Opstad, T.B., Pettersen, A.A., Weiss, T., et al., 2010. Gender differences of polymorphisms in the TFand TFPI genes, as related to phenotypes in patients with coronary heart disease and type-2 diabetes. Thromb. J., 8(1):7. [doi:10. 1186/1477-9560-8-7]
20. Pawlak, K., Ulazka, B., Mysliwiec, M., et al., 2012. Vascular endothelial growth factor and uPA/suPAR system in early and advanced chronic kidney disease patients: a new link between angiogenesis and hyperfibrinolysis? Transl. Res., 160(5):346–354. [doi:10.1016/j.trsl.2012.04.004]
21. Ruszkowska-Ciastek, B., Sokup, A., Socha, M.W., et al., 2014. A preliminary evaluation of VEGF-A, VEGFR1 and VEGFR2 in patients with well-controlled type 2 diabetes mellitus. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 15(6):575–581. [doi:10.1631/jzus.B1400024]
22. Ruszkowska-Ciastek, B., Sokup, A., Wernik, W., et al., 2015. Effect of uncontrolled hyperglycemia on levels of adhesion molecules in patients with diabetes mellitus type 2. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 16(5): 355–361. [doi:10.1631/jzus.B1400218]
23. Sherif, E.M., Elbarbary, N.S., Abd Al Aziz, M.M., et al., 2014. Plasma thrombin-activatable fibrinolysis inhibitor levels in children and adolescents with type 1 diabetes mellitus: possible relation to diabetic microvascular complications. Blood Coagul. Fibrinolysis, 25(5):451–457. [doi:10.1097/ MBC.0000000000000080]
24. Steffel, J., Lüscher, M.D., Tanner, F.C., 2006. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation, 113(5):722–731. [doi:10. 1161/CIRCULATIONAHA.105.567297]
25. Veron, D., Reidy, K.J., Bertuccio, C., et al., 2010. Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int., 77(11):989–999. [doi:10.1038/ki.2010.64]
26. Xu, L., Kanasaki, K., Kitada, M., et al., 2012. Diabetic angiopathy and angiogenic defects. Fibrogenesis Tissue Repair, 5(1):13. [doi:10.1186/1755-1536-5-13]
27. Yuan, J., Guo, Q., Qureshi, A.R., et al., 2013. Circulating vascular endothelial growth factor (VEGF) and its soluble receptor 1 (sVEGFR-1) are associated with inflammation and mortality in incident dialysis patients. Nephrol. Dial. Transplant., 28(9):2356–2363. [doi:10.1093/ndt/gft256]